Author details

Full Name

Keisuke Shindo

Affiliation

Graduate School of Medicine, Kyoto University

ORCID

Career Start Year

2002

Papers

H Index

Expertise

CM4AI Collaborator

Andrej Sali (CM4AI)

PMID	Paper Title	Journal Title	Published Year
36972660	HTLV-1 bZIP factor impairs DNA mismatch repair system.	Biochem Biophys Res Commun	2023
32533515	Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator.	Int J Hematol	2020
31914134	APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.	PLoS One	2020
32446377	Critical role of PP2A-B56 family protein degradation in HIV-1 Vif mediated G2 cell cycle arrest.	Biochem Biophys Res Commun	2020
30935695	A screening for DNA damage response molecules that affect HIV-1 infection.	Biochem Biophys Res Commun	2019
31073151	Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells.	Sci Rep	2019
31165764	Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation.	Sci Rep	2019
29077243	Dual inhibition of the mTORC1 and mTORC2 signaling pathways is a promising therapeutic target for adult T-cell leukemia.	Cancer Sci	2018
28993637	HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia.	Sci Rep	2017
27577680	Classical NF-ÎºB pathway is responsible for APOBEC3B expression in cancer cells.	Biochem Biophys Res Commun	2016
27758855	Core Binding Factor Î² Protects HIV, Type 1 Accessory Protein Viral Infectivity Factor from MDM2-mediated Degradation.	J Biol Chem	2016
25901786	ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction.	Nat Commun	2015
26601161	Abacavir, an anti-HIV-1 drug, targets TDP1-deficient adult T cell leukemia.	Sci Adv	2015
24465689	CKIP-1 is an intrinsic negative regulator of T-cell activation through an interaction with CARMA1.	PLoS One	2014
24986077	Small molecules that inhibit Vif-induced degradation of APOBEC3G.	Virol J	2014
24418540	Defining HIV-1 Vif residues that interact with CBFÎ² by site-directed mutagenesis.	Virology	2014
23430691	HIV-1 Vif: a guardian of the virus that opens up a new era in the research field of restriction factors.	Front Microbiol	2013
23150777	APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells.	Sci Rep	2012
24832226	A Comparison of Two Single-Stranded DNA Binding Models by Mutational Analysis of APOBEC3G.	Biology (Basel)	2012
22190037	Vif hijacks CBF-Î² to degrade APOBEC3G and promote HIV-1 infection.	Nature	2011
20308164	Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.	Nucleic Acids Res	2010
20971849	A single amino acid in human APOBEC3F alters susceptibility to HIV-1 Vif.	J Biol Chem	2010
20152150	Crystal structure of the APOBEC3G catalytic domain reveals potential oligomerization interfaces.	Structure	2010
19389408	An extended structure of the APOBEC3G catalytic domain suggests a unique holoenzyme model.	J Mol Biol	2009
18288108	Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.	Nature	2008
18501607	Evolution of HIV-1 isolates that use a novel Vif-independent mechanism to resist restriction by human APOBEC3G.	Curr Biol	2008
17869248	Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G.	FEBS Lett	2007
15254195	APOBEC3G targets specific virus species.	J Virol	2004
12970355	The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.	J Biol Chem	2003
12521218	Successful treatment with paclitaxel of advanced AIDS-associated Kaposi's sarcoma.	Intern Med	2002

1 - 30 of 30

Markus-Frederik Bohn

Department of Pharmaceutical Chemistry, University of California San Francisco

Career Start Year 2012

Number of shared co-authors 14

Yuqing Feng

University of Toronto

Career Start Year 2011

Number of shared co-authors 3

Jonas Demeulemeester

VIB-KU Leuven Center for Cancer Biology

Career Start Year 2010

Number of shared co-authors 0

Jennifer M Binning

H. Lee Moffitt Cancer Center and Research Institute

Career Start Year 2010

Number of shared co-authors 10

Gaelle Mercenne

University of Utah

Career Start Year 2009

Number of shared co-authors 7

Kei Sato

The Institute of Medical Science, The University of Tokyo

Career Start Year 2008

Number of shared co-authors 3

Koen Bartholomeeusen

Institute of Tropical Medicine

Career Start Year 2007

Number of shared co-authors 12

Will Dampier

Drexel University College of Medicine

Career Start Year 2007

Number of shared co-authors 0

Michael A Carpenter

University of Minnesota

Career Start Year 2006

Number of shared co-authors 10

Eytan Herzig

J. David Gladstone Institutesgrid.249878.8

Career Start Year 2005

Number of shared co-authors 2

Mary K Lewinski

University of California

Career Start Year 2005

Number of shared co-authors 2

Lara Manganaro

National Institute of Molecular Genetics, "Fondazione Romeo ed Enrica Invernizzi"

Career Start Year 2005

Number of shared co-authors 2

Stef??n R J??nsson

Institute for Experimental Pathology, University of Iceland

Career Start Year 2005

Number of shared co-authors 10

Jessica L Smith

Vaccine and Gene Therapy Institute, Oregon Health and Science University

Career Start Year 2005

Number of shared co-authors 2

Linda Chelico

University of Saskatchewan, College of Medicine

Career Start Year 2003

Number of shared co-authors 4

Felipe Diaz-Griffero

Albert Einstein College of Medicine

Career Start Year 2002

Number of shared co-authors 2

Renate K??nig

Paul-Ehrlich-Institut

Career Start Year 1998

Number of shared co-authors 2

Viviana Simon

Icahn School of Medicine at Mount Sinai

Career Start Year 1997

Number of shared co-authors 4

Greg J Towers

University College London

Career Start Year 1995

Number of shared co-authors 1

Wei Shao

Inc., Frederick National Laboratory for Cancer Research

Career Start Year 1993

Number of shared co-authors 2

Lubbertus C F Mulder

Icahn School of Medicine at Mount Sinai

Career Start Year 1993

Number of shared co-authors 2

Paul D Bieniasz

The Rockefeller University

Career Start Year 1993

Number of shared co-authors 2

Ren Sun

University of California los angeles

Career Start Year 1992

Number of shared co-authors 2

Matthew D Weitzman

The Children's Hospital of Philadelphia

Career Start Year 1992

Number of shared co-authors 0

Vicente Planelles

University of Utah

Career Start Year 1991

Number of shared co-authors 4

Pavel Sova

Altius Institute for Biomedical Sciences

Career Start Year 1990

Number of shared co-authors 0

Frederic D Bushman

Perelman School of Medicine, University of Pennsylvania

Career Start Year 1983

Number of shared co-authors 7

Michael Emerman

Fred Hutchinson Cancer Center

Career Start Year 1982

Number of shared co-authors 9

John Guatelli

University of California San Diego, USA VA San Diego Healthcare System

Career Start Year 1978

Number of shared co-authors 3

Ronald Swanstrom

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill

Career Start Year 1972

Number of shared co-authors 1

row(s) 1 - 30 of 30

Kotaro Shirakawa

Graduate School of Medicine, Kyoto University

Co-authored papers 12

Reuben S Harris

University of Texas Health San Antonio

Co-authored papers 11

Hiroshi Matsuo

Frederick National Laboratory for Cancer Research

Co-authored papers 6

Elena Harjes

Massey University

Co-authored papers 5

William L Brown

University of Minnesota

Co-authored papers 3

Ming Li

Department of Cancer Research Institute, University of South Australia

Co-authored papers 3

John S Albin

Massachusetts General Hospital

Co-authored papers 3

Rebecca S LaRue

Minnesota Supercomputing Institute, University of Minnesota

Co-authored papers 2

John D Gross

Department of Pharmaceutical Chemistry, University of California san francisco

Co-authored papers 2

Yves Pommier

Center for Cancer Research, National Cancer Institute

Co-authored papers 2

Mohan Somasundaran

University of Massachusetts Chan Medical School

Co-authored papers 1

Andrej Sali (CM4AI)

University of California San Francisco

Co-authored papers 1

Kathleen E Franks-Skiba

University of California, USA Quantitative Biosciences Institute (QBI) san francisco

Co-authored papers 1

David J Stanley

Department of Pharmaceutical Chemistry, University of California san francisco

Co-authored papers 1

Nevan J Krogan (CM4AI)

University of California San Francisco

Co-authored papers 1

Vinodh N Rajapakse

Co-authored papers 1

Cathal Mahon

Denali Therapeutics Inc.

Co-authored papers 1

Stefanie J??ger

Institute of Molecular Biosciences, Goethe University Frankfurt

Co-authored papers 1

Judd F Hultquist

Northwestern University Feinberg School of Medicine

Co-authored papers 1

Mary Munson

University of Massachusetts Chan Medical School

Co-authored papers 1

Brett D Anderson

University of Minnesota

Co-authored papers 1

Dong Young Kim

Seoul National University College of Medicine, Seoul National University Hospital

Co-authored papers 1

Joshua Kane

University of California, USA Quantitative Biosciences Institute (QBI) san francisco

Co-authored papers 1

Charles S Craik

Department of Pharmaceutical Chemistry, University of California san francisco

Co-authored papers 1

Shivender M D Shandilya

University of Massachusetts Medical School

Co-authored papers 1

Peter Cimermancic

Verily Life Sciences LLC

Co-authored papers 1

Celia A Schiffer

University of Massachusetts Chan Medical School

Co-authored papers 1

Alma L Burlingame

Department of Pharmaceutical Chemistry, University of California san francisco

Co-authored papers 1

Eunju Kwon

Yeungnam University

Co-authored papers 1

Linda Yen

Middlemore Hospital

Co-authored papers 1

1 - 30

Author Details

Column Actions

Recommended Authors

Collaborators